NCT07197138View on ClinicalTrials.gov

IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition

NARecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

September 30, 2027

Conditions
Depressive DisorderPost-Acute COVID-19 Syndrome
Interventions
DEVICE

Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS

iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.

Trial Locations (1)

80804

RECRUITING

Max-Planck-Institute of Psychiatry, Munich

All Listed Sponsors
lead

Max-Planck-Institute of Psychiatry

OTHER

NCT07197138 - IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | Biotech Hunter | Biotech Hunter